https://doi.org/10.4081/monaldi.2024.2947
Active versus latent pulmonary tuberculosis: which one is the appropriate distinguishing biomarker?
Submitted: February 7, 2024
Accepted: May 3, 2024
Published: July 25, 2024
Accepted: May 3, 2024
Abstract Views: 225
PDF_EARLY VIEW: 95
SUPPLEMENTARY MATERIAL: 10
SUPPLEMENTARY MATERIAL: 10
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
This study tried to assess the possibility of using the estimated levels of plasma expression of microRNAs (miR-) for distinguishing healthy subjects with latent pulmonary tuberculosis (LTB) from healthy controls (HC) and patients with active tuberculosis (ATB). Study participants included 30 newly diagnosed ATB patients, 30 of the households of ATB patients who were free of clinical manifestations, had normal chest radiography but had positive results on the whole-blood QuantiFERON tuberculosis (TB) Gold In-Tube (QFT-GIT) test (LTB patients), and 30 HC who were free of clinical symptoms and showed normal chest X-rays and negative QFT-GIT tests. All participants gave blood samples for quantitation of the plasma expression levels of miR- using the reverse transcription-quantitative polymerase chain reaction. Plasma levels of miR-150-5p were significantly downregulated in ATB samples than in other samples. However, miR-155-5p and miR-378-5p were significantly overexpressed in patients' samples compared to HC's samples and in ATB samples compared to LTB samples. On the contrary, plasma miR-4523-5p showed significant upregulation in LTB samples compared to ATB and HC samples, indicating insignificant in-between differences. The receiver operating characteristic curve analysis showed the ability of the estimated levels of the four miR- to differentiate TB patients from HC. Multivariate regression analysis defined expression levels of miR-155-5p and miR-378-5p as the significant biomarkers for distinguishing TB patients and levels of miR-378-5p and miR-4523-5p for identification of LTB patients. Pulmonary TB induces deregulated expression of miR-, according to the infection severity. An estimation of the expression levels of miR-378-5p and miR-4523-5p might be a reliable combination for identifying LTB patients.
Dheda K, Perumal T, Moultrie H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med 2022;10:603-22.
DOI: https://doi.org/10.1016/S2213-2600(22)00092-3
Furin J, Cox H, Pai M. Tuberculosis. Lancet 2019;393:1642-56.
DOI: https://doi.org/10.1016/S0140-6736(19)30308-3
World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015. Available from: https://iris.who.int/bitstream/handle/10665/136471/9789241548908_eng.pdf?sequence=1.
Kiazyk S, Ball TB. Latent tuberculosis infection: an overview. Can Commun Dis Rep 2017;43:62-6.
DOI: https://doi.org/10.14745/ccdr.v43i34a01
Palanivel J, Sounderrajan V, Thangam T, et al. Latent tuberculosis: challenges in diagnosis and treatment, perspectives, and the crucial role of biomarkers. Curr Microbiol 2023;80:392.
DOI: https://doi.org/10.1007/s00284-023-03491-x
MacPherson P, Lebina L, Motsomi K, et al. Prevalence and risk factors for latent tuberculosis infection among household contacts of index cases in two South African provinces: Analysis of baseline data from a cluster-randomised trial. PLoS One 2020;15:e0230376.
DOI: https://doi.org/10.1371/journal.pone.0230376
Vonnahme L, Raykin J, Jones M, et al. Using electronic health record data to measure the latent tuberculosis infection care cascade in safety-net primary care clinics. AJPM Focus 2023;2:100148.
DOI: https://doi.org/10.1016/j.focus.2023.100148
Bi D, Liang C, Huang X, et al. Clinical utilization of multiple antibodies of Mycobacterium tuberculosis for serodiagnosis evaluation of tuberculosis: a retrospective observational cohort study. Ann Med 2023;55:2238186.
DOI: https://doi.org/10.1080/07853890.2023.2238186
Wu X, Tan G, Ma J, et al. Assessment of the Cepheid 3-gene host response fingerstick blood test (MTB-HR) on rapid diagnosis of tuberculosis. Emerg Microbes Infect 2023;12:2261561.
DOI: https://doi.org/10.1080/22221751.2023.2261561
Siegel SAR, Cavanaugh M, Ku JH, et al. Specificity of QuantiFERON-TB Plus, a new-generation interferon gamma release assay. J Clin Microbiol 2018;56:e00629-18.
DOI: https://doi.org/10.1128/JCM.00629-18
Chen Y, Lee C, Hsiao C, et al. MicroRNA-23a-3p down-regulation in active pulmonary tuberculosis patients with high bacterial burden inhibits mononuclear cell function and phagocytosis through TLR4/TNF-α/TGF-β1/IL-10 signaling via targeting IRF1/SP1. Int J Mol Sci 2020;21:8587.
DOI: https://doi.org/10.3390/ijms21228587
Zhou R, Jia Y, Wang Y, et al. Elevating miR-378 strengthens the isoflurane-mediated effects on myocardial ischemia-reperfusion injury in mice via suppression of MAPK1. Am J Transl Res 2021;13:2350-64
Chakrabarty S, Kumar A, Raviprasad K, et al. Host and MTB genome encoded miRNA markers for diagnosis of tuberculosis. Tuberculosis 2019;116:37-43.
DOI: https://doi.org/10.1016/j.tube.2019.04.002
Angria N, Massi M, Bukhari A, et al. Expression of miRNA-29a-3p and IFN-γ as biomarkers in active and latent pulmonary tuberculosis. Ann Med Surg (Lond) 2022;83:104786.
DOI: https://doi.org/10.1016/j.amsu.2022.104786
Ann Daniel E, Sathiyamani B, Thiruvengadam K, et al. MicroRNAs as diagnostic biomarkers for Tuberculosis: a systematic review and meta-analysis. Front Immunol 2022;13:954396.
DOI: https://doi.org/10.3389/fimmu.2022.954396
Alijani E, Rad F, Katebi A, Ajdary S. Differential expression of miR-146 and miR-155 in active and latent tuberculosis infection. Iran J Public Health 2023;52:1749-57.
DOI: https://doi.org/10.18502/ijph.v52i8.13414
Sheng Y, Hua H, Yong Y, Zhou L. Identification of hub genes and typing of tuberculosis infections based on autophagy-related genes. Pol J Microbiol 2023;72:223-38.
DOI: https://doi.org/10.33073/pjm-2023-022
Zhou M, Yu G, Yang X, et al. Circulating microRNAs as biomarkers for the early diagnosis of childhood tuberculosis infection. Mol Med Rep 2016;13:4620-6.
DOI: https://doi.org/10.3892/mmr.2016.5097
Liu Q, Wang Y, Zheng Q, et al. MicroRNA-150 inhibits myeloid-derived suppressor cells proliferation and function through negative regulation of ARG-1 in sepsis. Life Sci 2021;278:119626.
DOI: https://doi.org/10.1016/j.lfs.2021.119626
Shi L, Zhang Y, Xia Y, et al. MiR-150-5p protects against septic acute kidney injury via repressing the MEKK3/JNK pathway. Cell Signal 2021;86:110101.
DOI: https://doi.org/10.1016/j.cellsig.2021.110101
Mohammadinasr M, Montazersaheb S, Molavi O, et al. Multiplex analysis of cerebrospinal fluid and serum exosomes micrornas of untreated relapsing remitting multiple sclerosis (RRMS) and proposing noninvasive diagnostic biomarkers. Neuromolecular Med 2023;25:402-14.
DOI: https://doi.org/10.1007/s12017-023-08744-3
Wu J, Lu C, Diao N, et al. Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol 2012;73:31-7.
DOI: https://doi.org/10.1016/j.humimm.2011.10.003
Shepelkova G, Evstifeev V, Tarasov R, et al. MicroRNAs as biomarkers of active pulmonary TB course. Microorganisms 2023;11:626.
DOI: https://doi.org/10.3390/microorganisms11030626
Fu Y, Shen J, Liu F, et al. Andrographolide suppresses pyroptosis in Mycobacterium tuberculosis-infected macrophages via the microRNA-155/Nrf2 axis. Oxid Med Cell Longev 2022;2022:1885066.
DOI: https://doi.org/10.1155/2022/1885066
Kathirvel M, Saranya S, Mahadevan S. Expression levels of candidate circulating microRNAs in pediatric tuberculosis. Pathog Glob Health 2020;114:262-70.
DOI: https://doi.org/10.1080/20477724.2020.1761140
Abdalla A, Alanazi A, Abosalif K, et al. MicroRNA-155, a double-blade sword regulator of innate tuberculosis immunity. Microb Pathog 2023;185:106438.
DOI: https://doi.org/10.1016/j.micpath.2023.106438
Sun X, Liu K, Zhao Y, Zhang T. High miRNA-378 expression has high diagnostic values for pulmonary tuberculosis and predicts adverse outcomes. BMC Mol Cell Biol 2022;23:14.
DOI: https://doi.org/10.1186/s12860-022-00413-w
Soonthornchai W, Tangtanatakul P, Meesilpavikkai K, et al. MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene. Sci Rep 2021;11:14186.
DOI: https://doi.org/10.1038/s41598-021-93616-8
Diotallevi F, Matacchione G, d'Agostino G, et al. Inflamma miR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study. Dermatol Ther (Heidelb) 2023;13:1377-87.
DOI: https://doi.org/10.1007/s13555-023-00931-1
Feng M, Li Z, Aau M, et al. Myc/ miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene 2011;30:2242-51.
DOI: https://doi.org/10.1038/onc.2010.602
Massi M, Hidayah N, Handayani I, et al. MicroRNA hsa-miR-425-5p and hsa-miR-4523 expressions as biomarkers of active pulmonary tuberculosis, latent tuberculosis infection, and lymph node tuberculosis. Noncoding RNA Res 2023;8:527-33.
DOI: https://doi.org/10.1016/j.ncrna.2023.07.001
Liang J, Zhou Z, Bo L, et al. Phosphoglycerate kinase 1 silencing by a novel microRNA microRNA-4523 protects human osteoblasts from dexamethasone through activation of Nrf2 signaling cascade. Cell Death Dis 2021;12:964.
DOI: https://doi.org/10.1038/s41419-021-04250-1
Ethics Approval
The final approval by the Local Ethical Committee, Benha University was obtained with approval number (Rc: 5 2 2024).How to Cite
Sarhan, Rizk Sayad R., Omnia Y. Habashy, Raafat R. Mohammed, and Yasmin M. Marei. 2024. “Active <i>versus< i> Latent Pulmonary Tuberculosis: Which One Is the Appropriate Distinguishing Biomarker?”. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2024.2947.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Evangelos Balis, Sotiris Kakavas, Steven Kompogiorgas, Konstantinos Kotsifas, Georgios Boulbasakos, Presentation of pulmonary tuberculosis and actinomyces co-infection as a lung mass: a literature review and unique case report , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Cuneyt Tetikkurt, Halil Yanardag, Metin Pehlivan, Muammer Bilir, Clinical features and prognostic significance of splenic involvement in sarcoidosis , Monaldi Archives for Chest Disease: Vol. 87 No. 3 (2017)
- Pratap Upadhya, Rohit Vadala, Arpitha A, Hospital treatment of severe acute exacerbation of chronic obstructive pulmonary disease in COVID-19 situation: back to basics , Monaldi Archives for Chest Disease: Vol. 90 No. 4 (2020)
- Anshul Mittal, Megha Varshney, Vidushi Rathi, Pranav Ish, High flow nasal cannula in acute hypercapnic exacerbation of chronic obstructive pulmonary disease: an emerging utility , Monaldi Archives for Chest Disease: Vol. 90 No. 1 (2020)
- F.J. de Serres, M. Luisetti, I. Ferrarotti, I. Blanco, E. Fernández-Bustillo, Alpha-1 antitrypsin deficiency in Italy: regional differences of the PIS and PIZ deficiency alleles , Monaldi Archives for Chest Disease: Vol. 63 No. 3 (2005): Pulmonary series
- I. Chkhaidze, T. Maglakelidze, N. Khaltaev, Chronic respiratory diseases at primary health care level in Georgia: the results of the pilot study , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- R.W. Dal Negro, R. Aquilani, S. Bertacco, F. Boschi, C. Micheletto, S. Tognella, Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia , Monaldi Archives for Chest Disease: Vol. 73 No. 1 (2010): Pulmonary series
- Y. Lacasse, L. Beaudoin, L. Rousseau, F. Maltais, Randomized trial of paroxetine in end-stage COPD , Monaldi Archives for Chest Disease: Vol. 61 No. 3 (2004): Pulmonary series
- Sara Albertini, Antonella Ciocca, Cristina Opasich, Gian Domenico Pinna, Franco Cobelli, Third phase of cardiac rehabilitation: a nurse-based “home-control†model , Monaldi Archives for Chest Disease: Vol. 76 No. 4 (2011): Cardiac series
- Maryam Hassan, Akbar Shoukat Ali, Ali Bin Sarwar Zubairi, Zahra Ali Padhani, Salman Kirmani, Huzaifa Ahmad, Zafar Fatmi, Jai K Das, Gene polymorphisms and risk of idiopathic pulmonary fibrosis: a systematic review and meta-analysis , Monaldi Archives for Chest Disease: Early Access
<< < 25 26 27 28 29 30 31 32 33 34 > >>
You may also start an advanced similarity search for this article.
